Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | EEF2K | O00418 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797453 | 0.75 | ALDH1A1 (0.41) | ALDH1A1HTTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL248053 | 0.72 | MAPT (0.51) | ALDH1A1HTTSMN1; SMN2NPSR1KMT2A | |
| SCHEMBL246611 | 0.71 | ALDH1A1 (0.47) | ALDH1A1HTTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL14108121 | 0.63 | RAB9A (0.41) | SMN1; SMN2RAB9ANPC1HPGDKMT2A | |
| SCHEMBL11006800 | 0.63 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL9419174 | 0.63 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL11001481 | 0.63 | SMN1; SMN2 (0.49) | ALDH1A1HTTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL22080016 | 0.62 | S1PR1 (0.44) | ALDH1A1HTTSMN1; SMN2RAB9AKMT2A | |
| SCHEMBL10940226 | 0.62 | SMN1; SMN2 (0.48) | ALDH1A1HTTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4620848 | 0.62 | HTT (0.56) | ALDH1A1HTTSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130171158-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-04 | — | — | US | claimed |
| WO-2012000036-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-05 | — | — | WO | claimed |
| US-20130171158-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-04 | — | — | US | disclosed |
| WO-2012000036-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171158-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | FBP1, G6PC1, G6PD | ALDH1A1 136/4885HTT 4382/4885SMN1; SMN2 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.